478 related articles for article (PubMed ID: 19769964)
1. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
[TBL] [Abstract][Full Text] [Related]
2. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death.
Angeles DC; Gan BH; Onstead L; Zhao Y; Lim KL; Dachsel J; Melrose H; Farrer M; Wszolek ZK; Dickson DW; Tan EK
Hum Mutat; 2011 Dec; 32(12):1390-7. PubMed ID: 21850687
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
4. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
6. Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation.
Greene ID; Mastaglia F; Meloni BP; West KA; Chieng J; Mitchell CJ; Gai WP; Boulos S
J Neurosci Res; 2014 Apr; 92(4):506-16. PubMed ID: 24375786
[TBL] [Abstract][Full Text] [Related]
7. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
Xiao Q; Yang S; Le W
J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
Niu J; Yu M; Wang C; Xu Z
J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
[TBL] [Abstract][Full Text] [Related]
9. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
Su YC; Qi X
Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
[TBL] [Abstract][Full Text] [Related]
12. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
14. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
Dusonchet J; Li H; Guillily M; Liu M; Stafa K; Derada Troletti C; Boon JY; Saha S; Glauser L; Mamais A; Citro A; Youmans KL; Liu L; Schneider BL; Aebischer P; Yue Z; Bandopadhyay R; Glicksman MA; Moore DJ; Collins JJ; Wolozin B
Hum Mol Genet; 2014 Sep; 23(18):4887-905. PubMed ID: 24794857
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
[TBL] [Abstract][Full Text] [Related]
16. Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.
Ohta E; Kawakami F; Kubo M; Obata F
Biochem Biophys Res Commun; 2013 Jan; 430(2):560-6. PubMed ID: 23220480
[TBL] [Abstract][Full Text] [Related]
17. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
[TBL] [Abstract][Full Text] [Related]
18. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.
Carballo-Carbajal I; Weber-Endress S; Rovelli G; Chan D; Wolozin B; Klein CL; Patenge N; Gasser T; Kahle PJ
Cell Signal; 2010 May; 22(5):821-7. PubMed ID: 20074637
[TBL] [Abstract][Full Text] [Related]
19. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
20. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
